TY - JOUR
T1 - Clinical Management and Outcomes of Nontuberculous Mycobacterial Infections in Solid Organ Transplant Recipients
T2 - A Multinational Case-control Study
AU - EMOTE (Epidemiology, Management and Outcomes of Non-tuberculous Mycobacteria Infections in Transplant Recipients in Europe and America) study group
AU - López-Medrano, Francisco
AU - Carver, Peggy L.
AU - Rutjanawech, Sasinuch
AU - Aranha-Camargo, Luis F.
AU - Fernandes, Ruan
AU - Belga, Sara
AU - Daniels, Shay Anne
AU - Mueller, Nicolas J.
AU - Burkhard, Sara
AU - Theodoropoulos, Nicole M.
AU - Postma, Douwe F.
AU - Van Duijn, Pleun J.
AU - Arnaiz De Las Revillas, Francisco
AU - Pérez Del Molino-Bernal, Concepción
AU - Hand, Jonathan
AU - Lowe, Adam
AU - Bodro, Marta
AU - Vanino, Elisa
AU - Fernández-Cruz, Ana
AU - Ramos-Martínez, Antonio
AU - Makek, Mateja Jankovic
AU - Bou Mjahed, Ribal
AU - Manuel, Oriol
AU - Kamar, Nassim
AU - Calvo-Cano, Antonia
AU - Rueda-Carrasco, Laura
AU - Muñoz, Patricia
AU - Álvarez-Uría, Ana
AU - Pérez-Recio, Sandra
AU - Sabé, Núria
AU - Rodríguez-Álvarez, Regino
AU - Silva, José Tiago
AU - Mularoni, Alessandra
AU - Vidal, Elisa
AU - Alonso-Titos, Juana
AU - Del Rosal, Teresa
AU - Classen, Annika Y.
AU - Goss, Charles W.
AU - Agarwal, Mansi
AU - Mejía-Chew, Carlos
N1 - Publisher Copyright:
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2025/2/1
Y1 - 2025/2/1
N2 - Background. The management and outcomes of nontuberculous mycobacterial (NTM) infections in solid organ transplant (SOT) recipients are poorly characterized. We aimed to describe the management and 1-y mortality of these patients. Methods. Retrospective, multinational, 1:2 matched case-control study included SOT recipients aged 12 y old or older diagnosed with NTM infection between January 1, 2008, and December 31, 2018. Controls were matched on transplanted organs, NTM treatment center, and posttransplant survival at least equal to the time to NTM diagnosis. The primary aim was 1-y mortality after NTM diagnosis. Differences between cases and controls were compared using the log-rank test, and Cox regression models were used to identify factors associated with mortality at 12 mo among cases. Results. In 85 patients and 169 controls, the median age at the time of SOT was 54 y (interquartile range, 40-62 y), 59% were men, and the lungs were the most common site of infection after SOT (57.6%). One-year mortality was significantly higher in cases than in controls (20% versus 3%; P < 0.001), and higher mortality was associated with lung transplantation (hazard ratio 3.27; 95% confidence interval [1.1-9.77]; P = 0.034). Median time (interquartile range) from diagnosis to treatment initiation (20 [4-42] versus 11 [3-21] d) or the reduction of net immunosuppression (36% versus 45%, hazard ratio 1.35 [95% CI, 0.41-4.43], P = 0.618) did not differ between survivors and those who died. Conclusions. NTM disease in SOT recipients is associated with a higher mortality risk, especially among lung transplant recipients. Time to NTM treatment and reduction in net immunosuppression were not associated with mortality.
AB - Background. The management and outcomes of nontuberculous mycobacterial (NTM) infections in solid organ transplant (SOT) recipients are poorly characterized. We aimed to describe the management and 1-y mortality of these patients. Methods. Retrospective, multinational, 1:2 matched case-control study included SOT recipients aged 12 y old or older diagnosed with NTM infection between January 1, 2008, and December 31, 2018. Controls were matched on transplanted organs, NTM treatment center, and posttransplant survival at least equal to the time to NTM diagnosis. The primary aim was 1-y mortality after NTM diagnosis. Differences between cases and controls were compared using the log-rank test, and Cox regression models were used to identify factors associated with mortality at 12 mo among cases. Results. In 85 patients and 169 controls, the median age at the time of SOT was 54 y (interquartile range, 40-62 y), 59% were men, and the lungs were the most common site of infection after SOT (57.6%). One-year mortality was significantly higher in cases than in controls (20% versus 3%; P < 0.001), and higher mortality was associated with lung transplantation (hazard ratio 3.27; 95% confidence interval [1.1-9.77]; P = 0.034). Median time (interquartile range) from diagnosis to treatment initiation (20 [4-42] versus 11 [3-21] d) or the reduction of net immunosuppression (36% versus 45%, hazard ratio 1.35 [95% CI, 0.41-4.43], P = 0.618) did not differ between survivors and those who died. Conclusions. NTM disease in SOT recipients is associated with a higher mortality risk, especially among lung transplant recipients. Time to NTM treatment and reduction in net immunosuppression were not associated with mortality.
UR - http://www.scopus.com/inward/record.url?scp=85199708749&partnerID=8YFLogxK
U2 - 10.1097/TP.0000000000005156
DO - 10.1097/TP.0000000000005156
M3 - Article
C2 - 39049076
AN - SCOPUS:85199708749
SN - 0041-1337
VL - 109
SP - e134-e141
JO - Transplantation
JF - Transplantation
IS - 2
ER -